ANNX
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 5.68 · operating margin 0.0%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 26 065 titres (~99 828,95 $ US)
- Insiders
- Love Douglas
- Total bought
-
$99,829
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-24
- Last synced
-
2026-09-25 21:09:17
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-25
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 5.681 | 10.372 | 14.718 | 11.096 | 11.391 | |
| Quick Ratio | 5.681 | 10.372 | 14.718 | 11.096 | 11.391 | |
| Solvency Ratio | -3.095 | -2.365 | -2.803 | -2.594 | -2.325 | |
| Cash Ratio | 3.801 | 1.622 | 12.556 | 6.262 | 3.442 | |
| Price To Earnings Ratio | -3.746 | -5.079 | -2.565 | -1.988 | -3.440 | |
| Price To Earnings Growth Ratio | -0.115 | 0.118 | 0.080 | 0.090 | 0.354 | |
| Forward Price To Earnings Growth Ratio | -0.115 | 0.118 | 0.080 | 0.090 | 0.354 | |
| Price To Earnings Diluted Ratio | -3.746 | -5.079 | -2.565 | -1.988 | -3.440 | |
| Price To Earnings Diluted Growth Ratio | -0.115 | 0.118 | 0.080 | 0.090 | 0.354 | |
| Price To Book Ratio | 3.679 | 2.405 | 1.371 | 1.223 | 1.898 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -4.175 | -5.973 | -2.831 | -2.301 | -4.085 | |
| Price To Operating Cash Flow Ratio | -4.178 | -5.973 | -2.836 | -2.430 | -4.149 | |
| Debt To Assets Ratio | 0.094 | 0.083 | 0.105 | 0.115 | 0.121 | |
| Debt To Equity Ratio | 0.124 | 0.099 | 0.125 | 0.142 | 0.149 | |
| Debt To Capital Ratio | 0.110 | 0.090 | 0.111 | 0.124 | 0.130 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.311 | 1.194 | 1.188 | 1.233 | 1.238 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.371 | -3.868 | -6.757 | -5.202 | -4.880 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.000 | 1.002 | 1.056 | 1.016 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -7.113 | -4.073 | -3.864 | -3.540 | -3.068 | |
| Capital Expenditure Coverage Ratio | -1,360.263 | -7,867.067 | -627.679 | -17.822 | -64.154 | |
| Dividend Paid And Capex Coverage Ratio | -1,360.263 | -7,867.067 | -627.679 | -17.822 | -64.154 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.150 | -5.079 | -1.134 | -1.255 | -3.121 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 5.681 | ▼-4.691 | ▼-4.970 |
| Quick Ratio | 5.681 | ▼-4.691 | ▼-4.970 |
| Solvency Ratio | -3.095 | ▼-0.730 | ▼-0.459 |
| Cash Ratio | 3.801 | ▲2.179 | ▼-1.736 |
| Price To Earnings Ratio | -3.746 | ▲1.333 | ▼-0.383 |
| Price To Earnings Growth Ratio | -0.115 | ▼-0.233 | ▼-0.220 |
| Forward Price To Earnings Growth Ratio | -0.115 | ▼-0.233 | ▼-0.220 |
| Price To Earnings Diluted Ratio | -3.746 | ▲1.333 | ▼-0.383 |
| Price To Earnings Diluted Growth Ratio | -0.115 | ▼-0.233 | ▼-0.220 |
| Price To Book Ratio | 3.679 | ▲1.274 | ▲1.564 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -4.175 | ▲1.797 | ▼-0.302 |
| Price To Operating Cash Flow Ratio | -4.178 | ▲1.795 | ▼-0.265 |
| Debt To Assets Ratio | 0.094 | ▲0.012 | ▼-0.009 |
| Debt To Equity Ratio | 0.124 | ▲0.025 | ▼-0.004 |
| Debt To Capital Ratio | 0.110 | ▲0.020 | ▼-0.003 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.312 | ▲0.117 | ▲0.079 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.372 | ▼-0.504 | ▲0.644 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▲0.001 | ▼-0.014 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -7.113 | ▼-3.039 | ▼-2.781 |
| Capital Expenditure Coverage Ratio | -1360.263 | ▲6506.804 | ▲627.134 |
| Dividend Paid And Capex Coverage Ratio | -1360.263 | ▲6506.804 | ▲627.134 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.150 | ▲1.929 | ▼-0.402 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $778.6M | $704.9M | $343.6M | $282.7M | $440.3M | |
| Enterprise value | $642.8M | $684.4M | $149.8M | $175.5M | $400.0M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -3.45x | -5.80x | -1.24x | -1.51x | -3.77x | |
| EV / Free cash flow | -3.45x | -5.80x | -1.24x | -1.43x | -3.71x | |
| EV / EBITDA | -3.15x | -5.08x | -1.13x | -1.25x | -3.12x | |
| Net debt / EBITDA | 0.67x | 0.15x | 1.47x | 0.77x | 0.31x | |
| Current ratio | 5.68x | 10.37x | 14.72x | 11.10x | 11.39x | |
| Income quality | 0.90x | 0.85x | 0.90x | 0.82x | 0.81x | |
| Graham net-net | $1 | $2 | $3 | $3 | $5 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $199.6M | $285.9M | $245.9M | $225.7M | $225.9M | |
| Invested capital | $225.4M | $315.3M | $278.7M | $261.7M | $264.1M | |
| Return on assets | -74.5% | -39.5% | -45.1% | -49.8% | -45.4% | |
| Operating ROA | -69.0% | -47.6% | -49.3% | -50.9% | -40.7% | |
| Return on tangible assets | -74.5% | -39.5% | -45.1% | -49.8% | -45.4% | |
| Return on equity | -97.7% | -47.2% | -53.6% | -61.4% | -56.2% | |
| Return on invested capital | -91.0% | -47.8% | -51.0% | -55.1% | -49.0% | |
| Return on capital employed | -92.1% | -48.2% | -51.4% | -55.4% | -49.3% | |
| Earnings yield | -26.5% | -19.6% | -39.1% | -50.2% | -29.6% | |
| Free cash flow yield | -24.0% | -16.7% | -35.3% | -43.5% | -24.5% | |
| Capex / Op. cash flow | -0.1% | -0.0% | -0.2% | -5.6% | -1.6% | |
| Capex / Depreciation | 6.3% | 0.7% | 9.0% | 309.9% | 77.3% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 1479d | 1102d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -1479d | -1102d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+10.5%EV / Sales n/aEV / EBITDA ▲+38.0%EV / Op. cash flow ▲+2.350Earnings yield ▼-0.069
Profitability
Return on equity ▼-0.505Return on assets ▼-0.350Return on invested capital ▼-0.431Return on capital employed ▼-0.439Operating ROA ▼-0.214Income quality ▲+0.048Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+376.754Operating cycle n/aCash conversion cycle ▼-376.754Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-4.690Net debt / EBITDA ▲+0.513Working capital ▼-86388000.000Invested capital ▼-89929000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+76.9%EV / Sales n/aEV / EBITDA ▼-1.0%EV / Op. cash flow ▲+0.320Earnings yield ▲+0.031
Profitability
Return on equity ▼-0.415Return on assets ▼-0.291Return on invested capital ▼-0.419Return on capital employed ▼-0.428Operating ROA ▼-0.283Income quality ▲+0.087Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-5.710Net debt / EBITDA ▲+0.352Working capital ▼-26388000.000Invested capital ▼-38767000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-24 Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal Trial Designed to Demonstrate Protection of Vision in Geographic Atrophy, with Month 15 Results Expected in the Fourth Quarter of 2026 BRISBANE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced two oral presentations on vonaprument at The Retina Society 59th Annual Scientific Meeting being held September 23-26, 2026 in Los Angeles, California.
- 2026-09-16 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-02 Annexon to Participate in Upcoming September Investor Conferences BRISBANE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following September investor conferences:
- 2026-08-17 Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 10, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-08-12 Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
- 2026-08-12 Annexon Q2 Earnings Call Highlights Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study''s existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.
- 2026-08-12 Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA Submission Expected in Q4 2026
- 2026-08-12 Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced the addition of a Month 24 dual primary endpoint to complement the current Month 15 primary endpoint in its Phase 3 ARCHER II trial, and launch of an open-label extension (OLE) study of vonaprument for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints.
- 2026-08-06 Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies
- 2026-07-30 Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration Expands Financial Capacity as Vonaprument and Tanruprubart Programs Advance Toward Registration